CoChat

Pharmacologic Management of Atrial Fibrillation: Established and Emerging Options

Open access
Kalus, James S. · 2009 · Journal of Managed Care Pharmacy
Cited by 57

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

BACKGROUND: In patients with atrial fibrillation (AF), antiarrhythmic drug therapy currently plays a greater role in maintaining sinus rhythm after cardioversion than it does in converting AF to sinus rhythm. Amiodarone is the most effective antiarrhythmic agent for maintaining sinus rhythm after cardioversion in patients with AF. However, its pharmacokinetics is complex; the drug interacts with many commonly used medications; and long-term use can cause thyroid dysfunction, hepatotoxicity, and other severe extracardiac adverse effects. The use of antiarrhythmic strategies in patients with AF has decreased because of evidence of greater safety and lower costs for hospitalization obtained from the use of rate-control strategies instead. Nevertheless, some patients require a rhythm-control strategy. Warfarin is used to prevent embolic stroke in many patients with AF, but its use is also complex and requires monitoring. Therefore, efforts have been made to develop antiarrhythmic agents with improved tolerability and anticoagulants that are easy to use. OBJECTIVES: To describe the 3 primary goals of pharmacotherapy in patients with AF, compare and contrast the efficacy and safety of established and investigational pharmacotherapies for AF, and recommend a drug regimen for an individual with AF based on patient-specific factors. SUMMARY: Currently available antiarrhythmic agents differ in their efficacy for maintaining sinus rhythm after cardioversion in AF patients with tolerability problems, comorbidities (particularly heart failure and renal impairment), and potential drug interactions. Hence, when selecting drug therapy to maintain sinus rhythm after cardioversion, it is important to take into consideration patient characteristics, including age, disease states, renal function, and concurrent drug therapies. Outpatient self-administration of single loading doses of flecainide or propafenone with what is referred to as the pill-in-the-pocket approach may be considered for carefully selected patients with recurrent episodes of symptomatic AF. The recently approved antiarrhythmic agent dronedarone has electrophysiologic properties similar to those of amiodarone, but its lack of iodine may improve upon the pharmacokinetic and tolerability issues associated with amiodarone. Vernakalant is another investigational antiarrhythmic agent that may prove useful for cardioversion and maintenance of sinus rhythm after cardioversion in patients with AF. New oral anticoagulants that do not require close laboratory monitoring and are simpler to use than warfarin have been used investigationally for prevention of venous thromboembolism and are in clinical trials for prevention of embolic stroke in patients with AF. CONCLUSIONS: Pharmacotherapy for patients with AF should be individualized based on patient-specific factors. New therapeutic options may become available to facilitate treatment of these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18553/jmcp.2009.15.s6-b.10

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 57

Metadata

Authors
Kalus, J. S.
Venue
Journal of Managed Care Pharmacy
Published
2009-08
Volume
15
Issue
6 Supp B
Pages
10-18
ISSN
  • 1083-4087 (ISSN-L)
  • 1944-706X
OpenAlex
W2187741580
Cited by
57
References
13
FWCI
7.12
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacologic Management of Atrial Fibrillation: Established and Emerging Options. https://app.cochat.ai/papers/10.18553/jmcp.2009.15.s6-b.10
The paper
Kalus, J. S. (2009). Pharmacologic Management of Atrial Fibrillation: Established and Emerging Options. Journal of Managed Care Pharmacy. https://doi.org/10.18553/jmcp.2009.15.s6-b.10

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.